Editorial: Anaplastic carcinoma of the thyroid - Will Aurora B light a path for treatment?

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 2, 2005, Pages 1243-1245

  Nikiforov, Yuri E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA B KINASE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; HESPERIDIN; HISTONE H3; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANEUPLOIDY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CHROMOSOMAL INSTABILITY; DRUG TARGETING; DYSPHAGIA; DYSPNEA; EDITORIAL; HUMAN; METASTASIS; MITOSIS; NECK TUMOR; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; THYROID CARCINOMA; THYROID FOLLICLE; UNITED STATES; VOCAL CORD PARALYSIS;

CARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN-SERINE-THREONINE KINASES; THYROID NEOPLASMS;

EID: 14044276411     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-2478     Document Type: Editorial

References (32)

1. Gilliland FD, Hunt WC, Morris DM, Key CR 1997 Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573
2. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR 2001 Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028-1034
3. Sherman SI 2003 Thyroid carcinoma. Lancet 361:501-511
4. Ain KB 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715-726
5. Veness MJ, Porter GS, Morgan GJ 2004 Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ J Surg 74:559-562
6. Wiseman SM, Loree TR, Rigual NR, Hicks Jr WL, Douglas WG, Anderson GR, Stoler DL 2003 Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 25:662-670
7. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404
8. Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL 2003 Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 27:1559-1564
9. Rodrigues RF, Roque L, Rosa-Santos J, Cid O, Soares J 2004 Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 90:492-496
10. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B 2002 Genome-wide appraisal of thyroid cancer progression. Am J Pathol 161:1549-1556
11. Schelfhout LJ, Cornelisse CJ, Goslings BM, Hamming JF, Kuipers-Dijkshoorn NJ, van de Velde CJ, Fleuren GJ 1990 Frequency and degree of aneuploidy in benign and malignant thyroid neoplasms. Int J Cancer 45:16-20
12. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D 1989 High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159-164
13. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184
14. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL 1999 Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 59:1811-1815
15. Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE, Fojo T 1998 Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 83:2516-2522
16. Fagin JA, Tang SH, Zeki K, Di Lauro R, Fusco A, Gonsky R 1996 Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 56:765-771
17. Moretti F, Nanni S, Farsetti A, Narducci M, Crescenzi M, Giuliacci S, Sacchi A, Pontecorvi A 2000 Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J Clin Endocrinol Metab 85:302-308
18. Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H, Yamashita S, Niwa M 2000 Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 85:4081-4086
19. Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, Spalletti-Cernia D, Laccetti P, Linardopoulos S, Chieffi P, Fusco A, Portella G 2005 Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90:928-935
20. Meraldi P, Honda R, Nigg EA 2004 Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 14:29-36
21. Katayama H, Brinkley WR, Sen S 2003 The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22:451-464
22. Shannon KB, Salmon ED 2002 Chromosome dynamics: new light on Aurora B kinase function. Curr Biol 12:R458-460
23. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, Tanino M, Terada Y, Tatsuka M 2002 Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 62:5168-5177
24. Terada Y, Tatsuka M, Suzuki F, Yasuda Y, Fujita S, Otsu M 1998 AIM-1: a mammalian midbody-associated protein required for cytokinesis. EMBO J 17:667-676
25. Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F, Terada Y 1998 Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 58:4811-4816
26. Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S, Suzuki F, Terada Y, Tatsuka M 1999 Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91:1160-1162
27. Ataki K, Nozaki K, Ueba T, Tatsuka M, Hashimoto N 2004 High expression of Aurora-B/Aurora and Ipl1-like midbody-associated protein (AIM-1) in astrocytomas. J Neurooncol 67:53-64
28. Capdeville R, Buchdunger E, Zimmermann J, Matter A 2002 Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502
29. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS 2003 Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161:267-280
30. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM 2003 The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161:281-294
31. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM 2004 VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262-267
32. Chen SS, Chang PC, Cheng YW, Tang FM, Lin YS 2002 Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J 21:4491-4499